Evidence map›Paper›PMID 28652880›Full record

ReviewCanadian Urological Association journal = Journal de l'Association des urologues du Canada2017

Testosterone monitoring for men with advanced prostate cancer: Review of current practices and a survey of Canadian physicians.

Bobby Shayegan, Frédéric Pouliot, Alan So, John Fernandes, Joseph Macri

Abstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in Canadian Urological Association journal = Journal de l'Association des urologues du Canada, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed.

  1. Review
  2. Article
  3. Article
  4. Article
  5. Article
  6. Testosterone suppression in the treatment of recurrent or metastatic prostate cancer - A Canadian consensus statement.Canadian Urological Association journal = Journal de l'Association des urologues du Canada · 2018
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors.

Bobby ShayeganDivision of Urology, Department of Surgery, McMaster University, Hamilton, ON.
Frédéric PouliotDivision of Urology, Department of Surgery, Université Laval, Quebec, QC.
Alan SoDepartment of Urologic Sciences, University of British Columbia, Vancouver, BC.
John FernandesDepartment of Pathology and Molecular Medicine, McMaster University, Hamilton, ON.
Joseph MacriDepartment of Pathology and Molecular Medicine, McMaster University, Hamilton, ON.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Androgen-deprivation therapy (ADT) is a standard of care in the treatment of advanced prostate cancer; however, testosterone monitoring practices for men undergoing ADT vary across Canada. Although a testosterone level of 1.7 nmol/L or lower has historically been defined as the accepted castrate level, newer assays with improved sensitivity have shown that both medical and surgical castration can suppress testosterone levels to below 0.7 nmol/L. This review explores the evidence supporting a redefinition of the castrate testosterone level as 0.7 nmol/L or lower, and presents results of a survey of testosterone monitoring practices among 153 Canadian urologists, uro-oncologists, and radiation oncologists who manage the treatment of men with hormone-sensitive prostate cancer.

Identifiers

PMID28652880
PMCPMC5472467

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.